LEXICON
No.84 October 3, 2011

Hemoglobin A1c (HbA1c)
ヘモグロビンA1c
HbA1c determined by the NGSP (National Glycohemoglobin Standardization Program) method
NGSP値 (HbA1c (NGSP))
HbA1c determined by the JDS (Japan Diabetes Society) method
JDS値 (HbA1c (JDS; 日本糖尿病学会))

Hemoglobin A1c (HbA1c値) is a kind of glycated hemoglobin (糖化ヘモグロビン) measured to determine the average plasma glucose concentration over a prolonged period of time. The amount of HbA1c as a percentage of the total amount of hemoglobin is used as...

To read the full story

LEXICON

By Philip Carrigan

The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…

By Takashi Ebisawa

Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

By Ken Yoshino

Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…

For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…